Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRUTH Study: Dasatinib and Quercetin for Fibrotic NAFLD
NCT05506488Phase 2Completed
- Sponsor
- University of Amsterdam
- Start
- Jul 2023
- Primary completion
- Feb 2026
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of dasatinib, quercetin in non-alcoholic fatty liver disease (NAFLD), Liver Fibrosis (LF), sponsored by University of Amsterdam. Started Jul 2023; status: completed.
02
Drugs
dasatinibquercetin
03
Conditions
non-alcoholic fatty liver disease (NAFLD)Liver Fibrosis (LF)
Beyond the preview
Go deeper on NCT05506488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05506488.